Despite this “epigenetic drift”, CML-IPSC-derived CD45+/CD34+ cells still retain the potential to acquire myeloid and erythroid differentiation capabilities in vitro and in vivo and can give rise to typical CML phenotypes, including CD15+/CD14+/GlyA+ [145]. This evidence concerns the gene PTPRC and chronic myelogenous leukemia, BCR-ABL1 positive.